公开(公告)号：US11014926B2

公开(公告)日：2021-05-25

申请号：US16378809

申请日：2019-04-09

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E Webber

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20190330216A1

公开(公告)日：2019-10-31

申请号：US16378809

申请日：2019-04-09

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E Webber

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.